What changed
2026-09-10 01:11 UTC → 2026-09-11 01:54 UTC ·
added
removed
A study by IQVIA projects significant growth in the The global pharmaceutical market through 2030. Total pharmaceutical spending is expected to exceed $2.6 trillion, with an annual growth rate of 5% to 8% and total drug consumption reaching 4 trillion daily doses. Growth is primarily attributed to four therapeutic categories: oncology, immunology, diabetes, and obesity. While high-income regions like North America, Western Europe, and Japan oncology markets are expected projected to see stabilizing growth, China is identified as the fastest-growing market, with drug use potentially doubling by 2030. Research indicates that 76% of global market experience substantial growth will stem from the United States and 14 developed nations, reflecting a broader trend toward the use of high-cost, innovative medications. Recent projections further highlight the expansion of through the oncology sector. The global cancer diagnostics market is expected to grow from $28.58 billion in 2026 to $44.69 billion by 2030, a compound annual growth rate of 11.8%, early 2030s, driven by innovative therapies and advancements in artificial intelligence, next-generation sequencing, and molecular diagnostics. Additionally, the breast cancer drugs market While total pharmaceutical spending is projected expected to reach $61.19 billion exceed $2.6 trillion by 2030, fueled by rising incidence rates and innovations in precision medicine and targeted therapies. Further expansion is anticipated in specialized oncology sectors are seeing even more rapid expansion. In the oncology segment, the hematologic cancer therapeutics market, which market is projected forecasted to grow from an estimated $74.6 billion in 2025 to $138.8 billion by 2032, representing a 9.2% CAGR. 2032. This growth is driven by increasing diagnoses of leukemia, lymphoma, and multiple myeloma. The market sector remains highly concentrated, with the top ten companies expected to account for approximately 81% of sales in 2025. Additional Further specialized growth is noted in the gamma delta T cell cancer therapy market, which is projected to reach $4.94 billion by 2030 with a compound annual growth rate (CAGR) of 18.4%, and the thyroid cancer drug market, which is expected to reach $2.39 billion by 2030. Diagnostic and intervention markets are also seeing upward trends. expanding. The hematopoietic stem cell transplantation global cancer diagnostics market is forecasted expected to reach $8.57 $44.69 billion by 2030, supported by gene-modified cell therapies. In diagnostics, while the histology market is projected to rise from $8.9 billion in 2026 to $14.5 billion by 2031. Additionally, the hematopoietic stem cell transplantation market is forecasted to reach $8.57 billion by 2030. Beyond oncology, the peripheral vascular intervention product market is expected to grow from approximately $81.7 billion in 2025 to $131.18 billion by 2032, driven by aging populations and increased prevalence of vascular diseases.